{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:13:41Z","timestamp":1787008421143,"version":"build-2736575974"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Evolus, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite a growing interest among men in cosmetic procedures such as botulinum toxin, comparator clinical trial data in this population are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The authors sought to compare the efficacy and safety of prabotulinumtoxinA and onabotulinumtoxinA for the treatment of males with moderate to severe glabellar lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post-hoc analyses were performed on the subpopulation of male patients treated with either a single dose of 20 U prabotulinumtoxinA (n\u2005=\u200525) or 20 U onabotulinumtoxinA (n\u2005=\u200531) in the EVB-003 Phase III glabellar line clinical study. One key efficacy endpoint was the proportion of responders with a\u2005\u22651-point improvement from baseline at maximum frown on the 4-point Glabellar Line Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with onabotulinumtoxinA-treated males, the percentages of responders who had a\u2005\u22651-point improvement on the Glabellar Line Scale at maximum frown were higher at all postbaseline time points for prabotulinumtoxinA-treated males (P\u2005&amp;gt;\u20050.05 at all visits) by an absolute overall mean difference of 10.1% across all visits. Similar trends were observed for efficacy endpoints based on global aesthetic improvement and subject satisfaction. PrabotulinumtoxinA-treated males had a higher incidence of treatment-related headache and eyelid ptosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The percentages of patients who met the definition of a responder were higher at almost all time points examined for prabotulinumtoxinA-treated males. Despite the high level of consistency across all measures, differences between the 2 treatment groups did not reach statistical significance. Further study is warranted to establish if these post-hoc analyses observations are reproducible in a larger male patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence: 1<\/jats:title>\n                    <jats:p\/>\n                  <\/jats:sec>","DOI":"10.1093\/asj\/sjac210","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T21:29:29Z","timestamp":1659562169000},"page":"1460-1469","source":"Crossref","is-referenced-by-count":15,"title":["PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data"],"prefix":"10.1093","volume":"42","author":[{"given":"Nowell","family":"Solish","sequence":"first","affiliation":[{"name":"University of Toronto , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ascher","sequence":"additional","affiliation":[{"name":"Paris Academy , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui L","family":"Avelar","sequence":"additional","affiliation":[{"name":"Evolus, Inc. , Newport Beach, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vince","family":"Bertucci","sequence":"additional","affiliation":[{"name":"Division of Dermatology, University of Toronto , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Bodokh","sequence":"additional","affiliation":[{"name":"Practicien Hospitalier, Service de Dermatologie, Cannes Hospital Simone Veil , Cannes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Carruthers","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of British Columbia , Vancouver, BC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Cartier","sequence":"additional","affiliation":[{"name":"Centre M\u00e9dical Saint-Jean , Arras , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Delmar","sequence":"additional","affiliation":[{"name":"private practice in Cap d\u2019Antibes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Denfeld","sequence":"additional","affiliation":[{"name":"private practice in Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Heckmann","sequence":"additional","affiliation":[{"name":"Ludwig Maximilian Universit\u00e4t , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Hed\u00e9n","sequence":"additional","affiliation":[{"name":"Karolinska Institute, Art Clinic , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Hilton","sequence":"additional","affiliation":[{"name":"private practice in D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Inglefield","sequence":"additional","affiliation":[{"name":"private practice in London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ogilvie","sequence":"additional","affiliation":[{"name":"private practice in Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold-Josef","family":"Rzany","sequence":"additional","affiliation":[{"name":"private practice in Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Sattler","sequence":"additional","affiliation":[{"name":"Rosenpark Research , Darmstadt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebastian","sequence":"additional","affiliation":[{"name":"private practice in Mahlow, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Swift","sequence":"additional","affiliation":[{"name":"McGill University , Montreal, PQ , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Tr\u00e9vidic","sequence":"additional","affiliation":[{"name":"private practice in Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"2022121421381164200_CIT0001","author":"International Society of Aesthetic Plastic Surgery"},{"key":"2022121421381164200_CIT0002"},{"key":"2022121421381164200_CIT0003","author":"American Society of Plastic Surgeons"},{"issue":"10","key":"2022121421381164200_CIT0004","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/dss.0000000000000876","article-title":"Facial treatment preferences among aesthetically oriented men","volume":"42","author":"Jagdeo","year":"2016","journal-title":"Dermatol Surg"},{"issue":"10","key":"2022121421381164200_CIT0005","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/dsu.12302","article-title":"Botulinum toxin in men: review of relevant anatomy and clinical trial data","volume":"39","author":"Keaney","year":"2013","journal-title":"Dermatol Surg"},{"key":"2022121421381164200_CIT0006","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1097\/dss.0000000000001293","article-title":"Signs of facial aging in men in a diverse, multinational study: timing and preventive behaviors","volume":"43","author":"Rossi","year":"2017","journal-title":"Dermatol Surg"},{"issue":"10","key":"2022121421381164200_CIT0007","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/j.1524-4725.2005.31206","article-title":"Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids","volume":"31","author":"Carruthers","year":"2005","journal-title":"Dermatol Surg"},{"issue":"12","key":"2022121421381164200_CIT0008","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1111\/j.1524-4725.2009.01235.x","article-title":"Randomized, placebo-controlled study of new botulinum toxin type A for treatment of glabellar lines: efficacy and safety","volume":"35","author":"Brandt","year":"2009","journal-title":"Dermatol Surg"},{"issue":"5","key":"2022121421381164200_CIT0009","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1097\/prs.0b013e3181b5641b","article-title":"Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study","volume":"124","author":"Kane","year":"2009","journal-title":"Plast Reconstr Surg"},{"issue":"6 Suppl","key":"2022121421381164200_CIT0010","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.asj.2009.09.012","article-title":"An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A \u2013 ABO for the treatment of glabellar lines","volume":"29","author":"Baumann","year":"2009","journal-title":"Aesthet Surg J"},{"issue":"Suppl 2","key":"2022121421381164200_CIT0011","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1097\/dss.0000000000001295","article-title":"Efficacy of incobotulinumtoxinA for the treatment of glabellar frown lines in male subjects: post-hoc analyses from randomized, double-blind pivotal studies","volume":"43","author":"Jones","year":"2017","journal-title":"Dermatol Surg"},{"issue":"2","key":"2022121421381164200_CIT0012","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/dss.0000000000002047","article-title":"Efficacy, patient-reported outcomes, and safety in male subjects treated with onabotulinumtoxinA for improvement of moderate to severe horizontal forehead lines","volume":"46","author":"Keaney","year":"2020","journal-title":"Dermatol Surg"},{"issue":"6","key":"2022121421381164200_CIT0013","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1529-8019.2007.00156.x","article-title":"Botox in men","volume":"20","author":"Flynn","year":"2007","journal-title":"Dermatol Ther"},{"issue":"3 Pt 2","key":"2022121421381164200_CIT0014","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/dsu.12147","article-title":"The convergence of medicine and neurotoxins: A focus on botulinum toxin type A and its application in aesthetic medicine \u2013 a global, evidence-based botulinum toxin consensus education initiative. Part I: botulinum toxin in clinical and cosmetic practice","volume":"39","author":"Carruthers","year":"2013","journal-title":"Dermatol Surg"},{"issue":"5","key":"2022121421381164200_CIT0015","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00266-013-0178-1","article-title":"Understanding the functional anatomy of the frontalis and glabellar complex for optimal aesthetic botulinum toxin type A therapy","volume":"37","author":"Lorenc","year":"2013","journal-title":"Aesthet Plast Surg"},{"issue":"Suppl 1","key":"2022121421381164200_CIT0016","first-page":"s5","article-title":"Re-examining the optimal use of neuromodulators and the changing landscape: a consensus panel update","volume":"19","author":"Kaminer","year":"2020","journal-title":"J Drugs Dermatol"},{"issue":"Suppl 5","key":"2022121421381164200_CIT0017","doi-asserted-by":"publisher","first-page":"40S","DOI":"10.1097\/prs.0000000000001729","article-title":"Ethnic and gender considerations in the use of facial injectables: male patients","volume":"136","author":"De Maio","year":"2015","journal-title":"Plast Reconstr Surg"},{"issue":"4","key":"2022121421381164200_CIT0018","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/jocd.12247","article-title":"Specific aspects of a combined approach to male face correction: botulinum toxin A and volumetric fillers","volume":"15","author":"Scherer","year":"2016","journal-title":"J Cosmet Dermatol"},{"issue":"Suppl 2","key":"2022121421381164200_CIT0019","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1097\/dss.0000000000001375","article-title":"Aesthetic treatment with botulinum toxin: approaches specific to men","volume":"43","author":"Green","year":"2017","journal-title":"Dermatol Surg"},{"issue":"1","key":"2022121421381164200_CIT0020","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.det.2017.09.005","article-title":"The use of neurotoxins in the male face","volume":"36","author":"Jones","year":"2018","journal-title":"Dermatol Clin"},{"issue":"1","key":"2022121421381164200_CIT0021","first-page":"19","article-title":"The male aesthetic patient: facial anatomy, concepts of attractiveness, and treatment patterns","volume":"17","author":"Keaney","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"2022121421381164200_CIT0022","first-page":"216","article-title":"Comparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: a pilot study","volume":"11","author":"Oliveira de Morais","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"2022121421381164200_CIT0023","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1097\/dss.0000000000002294","article-title":"Demographics of men and minorities in cosmetic clinical trials of botulinum toxin and hyaluronic acid fillers","volume":"46","author":"Roman","year":"2020","journal-title":"Dermatol Surg"},{"issue":"4","key":"2022121421381164200_CIT0024","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/asj\/sjz110","article-title":"A multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects","volume":"40","author":"Rzany","year":"2020","journal-title":"Aesthet Surg J"},{"key":"2022121421381164200_CIT0025","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/ccid.S41537","article-title":"Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study","volume":"6","author":"Rappl","year":"2013","journal-title":"Clin Cosmet Investigational Dermatol"},{"issue":"2","key":"2022121421381164200_CIT0026","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/ijd.12627","article-title":"Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study","volume":"54","author":"Won","year":"2015","journal-title":"Int J Dermatol"},{"issue":"12","key":"2022121421381164200_CIT0027","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1097\/DSS.0000000000001920","article-title":"Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow\u2019s feet: a Phase 3, multicenter, randomized, double-blind, split-face study","volume":"45","author":"Cheon","year":"2019","journal-title":"Derm Surg"},{"issue":"9","key":"2022121421381164200_CIT0028","first-page":"1041","article-title":"Consideration of muscle mass in glabellar line treatment with botulinum toxin type A","volume":"11","author":"Monheit","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"2022121421381164200_CIT0029","doi-asserted-by":"publisher","first-page":"ojab036","DOI":"10.1093\/asjof\/ojab036","article-title":"High-dose neuromodulators: a roundtable on making sense of the data in real-world clinical practice","volume":"3","author":"Fabi","year":"2021","journal-title":"Aesthet Surg J Open Forum"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjac210\/45866073\/sjac210.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjac210\/47888473\/sjac210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjac210\/47888473\/sjac210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T16:38:37Z","timestamp":1671035917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/42\/12\/1460\/6654899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,8,4]]},"published-print":{"date-parts":[[2022,12,14]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjac210","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,8,4]]}}}